Annuncio • Mar 07
Cellid, Co., Ltd., Annual General Meeting, Mar 31, 2026 Cellid, Co., Ltd., Annual General Meeting, Mar 31, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 1, gwanak-ro, gwanak-gu, seoul South Korea New Risk • Jan 28
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shareholders have been substantially diluted in the past year (40% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (₩101.2b market cap, or US$70.7m). Annuncio • Jun 18
Cellid, Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 35.784 billion. Cellid, Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 35.784 billion.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 8,400,000
Price\Range: KRW 4260
Discount Per Security: KRW 76.68
Transaction Features: Rights Offering New Risk • May 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (8.9% average weekly change). Market cap is less than US$100m (₩84.0b market cap, or US$60.0m). New Risk • Apr 23
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩78.5b market cap, or US$55.1m). Annuncio • Mar 19
Cellid, Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 24.15 billion. Cellid, Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 24.15 billion.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 8,400,000
Price\Range: KRW 2875
Transaction Features: Rights Offering Annuncio • Feb 27
Cellid, Co., Ltd., Annual General Meeting, Mar 26, 2025 Cellid, Co., Ltd., Annual General Meeting, Mar 26, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 1, gwanak-ro, gwanak-gu, seoul South Korea New Risk • Nov 28
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩25b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩25b free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 25% per year over the past 5 years. Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Minor Risks Revenue is less than US$5m (₩2.3b revenue, or US$1.6m). Market cap is less than US$100m (₩120.1b market cap, or US$86.1m). New Risk • Aug 23
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 117% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (27% average weekly change). Earnings have declined by 30% per year over the past 5 years. Shareholders have been substantially diluted in the past year (117% increase in shares outstanding). Revenue is less than US$1m (₩914m revenue, or US$684k). Annuncio • Aug 08
Cellid, Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 23.175 billion. Cellid, Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 23.175 billion.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 6,422,072
Price\Range: KRW 3090
Discount Per Security: KRW 49.44
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 1,077,928
Price\Range: KRW 3090
Discount Per Security: KRW 49.44
Transaction Features: Rights Offering New Risk • Jul 23
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (40% increase in shares outstanding). Market cap is less than US$100m (₩31.1b market cap, or US$22.4m). New Risk • May 27
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩18b free cash flow). Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Shareholders have been diluted in the past year (40% increase in shares outstanding). Market cap is less than US$100m (₩39.4b market cap, or US$29.0m). New Risk • Sep 26
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 40% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩11b free cash flow). Earnings have declined by 44% per year over the past 5 years. Revenue is less than US$1m (₩480m revenue, or US$356k). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (40% increase in shares outstanding). Market cap is less than US$100m (₩57.6b market cap, or US$42.8m). New Risk • Jun 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩11b free cash flow). Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m (₩480m revenue, or US$373k). Minor Risks Share price has been volatile over the past 3 months (8.2% average weekly change). Market cap is less than US$100m (₩64.2b market cap, or US$49.9m). Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. No independent directors (8 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Annuncio • Mar 21
Cellid, Co., Ltd. announced that it has received KRW 19 billion in funding On March 19, 2021, Cellid, Co., Ltd. (KOSDAQ:A299660) closed the transaction. Annuncio • Mar 19
Cellid, Co., Ltd. announced that it expects to receive KRW 19 billion in funding Cellid, Co., Ltd. (KOSDAQ:A299660) announced a private placement of 2nd series unregistered non-guaranteed private equity convertible bonds for gross proceeds of KRW 19,000,000,000 on March 17, 2021. The transaction will include participation from Daily Bio Health Care 1 Startup Venture Private Equity Joint Venture. The bonds will carry a zero coupon rate and zero yield to maturity. The bonds will mature on March 19, 2026. The bonds will be fully convertible into 515,296 shares of the company at a price of KRW 36,872 per share between the period of March 19, 2022 to February 19, 2026. The transaction has been approved by the board of directors of the company. The expected payment date and subscription date is March 19, 2021. Annuncio • Feb 25
Cellid, Co., Ltd., Annual General Meeting, Mar 24, 2021 Cellid, Co., Ltd., Annual General Meeting, Mar 24, 2021, at 10:00 Korea Standard Time. Is New 90 Day High Low • Jan 13
New 90-day low: ₩37,650 The company is down 24% from its price of ₩49,250 on 15 October 2020. The South Korean market is up 29% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 23% over the same period. Is New 90 Day High Low • Oct 05
New 90-day high: ₩50,700 The company is up 81% from its price of ₩28,050 on 07 July 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 5.0% over the same period.